Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) marked $19.17 per share on Wednesday, down from a previous closing price of $19.45. While Crinetics Pharmaceuticals Inc. has underperformed by -1.44%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CRNX rose by 5.39%, with highs and lows ranging from $24.58 to $15.23, whereas the simple moving average jumped by 2.14% in the last 200 days.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
On April 24, 2023, Piper Sandler started tracking Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) recommending Overweight.
Analysis of Crinetics Pharmaceuticals Inc. (CRNX)
Further, the quarter-over-quarter decrease in sales is -12.90%, showing a negative trend in the upcoming months.
In order to gain a clear picture of Crinetics Pharmaceuticals Inc.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -52.60% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 11.60, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 489.48K can be a very valuable indicator of volatility for CRNX stock. On a monthly basis, the volatility of the stock is set at 4.08%, whereas on a weekly basis, it is put at 3.99%, with a gain of 1.64% over the past seven days. Furthermore, long-term investors anticipate a median target price of $46.89, showing growth from the present price of $19.17, which can serve as yet another indication of whether CRNX is worth investing in or should be passed over.
How Do You Analyze Crinetics Pharmaceuticals Inc. Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.30%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 105.36% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in CRNX shares?
The recent increase in stakes in CRNX appears to be a result of several institutional investors and hedge funds increasing their positions. Driehaus Capital Management LLC’s position in CRNX has decreased by -5.96% in the first quarter. The company now owns 5,289,519 shares of the stock, with a value of $95.32 million, following the sale of -335,225 additional shares during the last quarter. Wellington Management Co. LLP made another increased to its shares in CRNX during the first quarter, upping its stake by 29.63%. During the last quarter, the company picked up 831,041 additional shares for a total stake of worth $65.51 million, bringing number of shares owned by the company to 3,635,526.
During the first quarter, BlackRock Fund Advisors added a 11,906 position in CRNX. Perceptive Advisors LLC sold an additional -0.48 million shares in the last quarter, decreasing its holdings by -11.99%, now holding 3.55 million shares worth $64.06 million. CRNX shares are owned by institutional investors to the tune of 105.36% at present.
